Cited by 215Atrial Fibrillation Management and OutcomesCardiac Arrhythmias and TreatmentsCardiac electrophysiology and arrhythmias

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Intravenous Dofetilide, a Class III Antiarrhythmic Agent, for the Termination of Sustained Atrial Fibrillation or Flutter

Open access

Falk, Rodney H., Pollak, Arthur, Singh, Steven N., Friedrich, Tilman·1997·Journal of the American College of Cardiology

DOI 10.1016/s0735-1097(96)00506-2

Open this paper in CoChat — free account Open PDF

Abstract

OBJECTIVES: This study sought to determine the safety and efficacy of a single bolus of intravenous dofetilide, a pure class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. BACKGROUND: Dofetilide is a highly selective blocker of the rapid component of the delayed rectifier current causing action potential prolongation. These effects, and preliminary clinical data, suggest that it may be effective in the treatment of atrial fibrillation and flutter. METHODS: Ninety-one patients with sustained atrial fibrillation (75 patients) or flutter (16 patients) were entered into a double-blind, randomized multicenter study of one of two doses of dofetilide (4 or 8 micrograms/kg body weight) or placebo. RESULTS: Dofetilide effectively terminated the arrhythmia in 31% of patients receiving 8 micrograms/kg, a statistically significant difference from those receiving 4 micrograms/kg (conversion rate 12.5%, p < 0.05) or placebo (no conversion, p < 0.01). Patients with atrial flutter had a greater response to dofetilide (54% conversion rate) than those with atrial fibrillation (14.5% conversion rate, p < 0.001). CONCLUSIONS: Intravenous dofetilide can convert sustained atrial fibrillation or flutter to sinus rhythm. However, its efficacy is greater in flutter--a response that contrasts with the poorer response seen with class I agents. This finding potentially represents an important advance in the pharmacologic termination of atrial flutter.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s0735-1097(96)00506-2

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents.
Sanguinetti, M. C., & Jurkiewicz, N. K. (1990) · The Journal of General Physiology · doi:10.1085/jgp.96.1.195 · Cited by 1,462
Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials.
Coplen, S. E., Antman, E. M., Berlin, J. A., Hewitt, P., & Chalmers, T. C. (1990) · Circulation · doi:10.1161/01.cir.82.4.1106 · Cited by 946
Digoxin for Converting Recent-Onset Atrial Fibrillation to Sinus Rhythm
Falk, R. H., Knowlton, A. A., Bernard, S. A., Gotlieb, N. E., & Battinelli, N. J. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-106-4-503 · Cited by 335
Self-citation
Voltage- and time-dependent block of the delayed K+ current in cardiac myocytes by dofetilide.
Carmeliet, E. E. (1992) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10827-6 · Cited by 322
Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension
Capucci, A., Lenzi, T., Boriani, G., Trisolino, G., Binetti, N., Cavazza, M., Fontana, G. A., & Magnani, B. (1992) · The American Journal of Cardiology · doi:10.1016/0002-9149(92)91392-h · Cited by 227
Cesium chloride-induced long QT syndrome: demonstration of afterdepolarizations and triggered activity in vivo.
Levine, J. H., SPEAR, J. F., Guarnieri, T., Weisfeldt, M. L., LANGEN, C. D. D., Becker, L. C., & Moore, E. N. (1985) · Circulation · doi:10.1161/01.cir.72.5.1092 · Cited by 205
UK-68,798: a novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells.
Gwilt, M., Arrowsmith, J. E., Blackburn, K. J., Burges, R. A., Cross, P. E., Dalrymple, H. W., & Higgins, A. J. (1990) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23172-x · Cited by 187
Rate-Dependent Class III Antiarrhythmic Action, Negative Chronotropy, and Positive Inotropy of a Novel Ik Blocking Drug, UK-68,798
Tande, P. M., Bjørnstad, H., Yang, T., & Refsum, H. (1990) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199009000-00008 · Cited by 177
Validation of double-spike electrograms as markers of conduction delay or block in atrial flutter
Cosío, F. G., Arribas, F., Barbero, J. M., Kallmeyer, C., & Goicolea, A. (1988) · The American Journal of Cardiology · doi:10.1016/0002-9149(88)91065-x · Cited by 155
Sotalol, hypokalaemia, syncope, and torsade de pointes.
McKibbin, J. K., Pocock, W. A., Barlow, J. B., Millar, R. N. S., & Obel, I. W. P. (1984) · Heart · doi:10.1136/hrt.51.2.157 · Cited by 150

Show all 30 references

Research works printed but not linked: 3

Bashir, 1992, Efficacy and safety of dofetilide, a new class III antiarrhythmic agent in recurrent ventricular tachycardia [abstract], Br Heart J, 68, 116
Brachman, 1992, The efficacy and safety of oral dofetilide in patients with sustained ventricular tachycardia [abstract], Circulation, 86 Suppl I, I-265
Hohnloser, 1992, Incidence, type and dose-dependence of proarrhythmic events during sotalol therapy in patients treated for sustained VT/VF [abstract], PACE, 15, 551

Sorted by citations

Items 101–200 of 214

Cardiac and hemodynamic effects of intravenous dofetilide in patients with heart failure
Rousseau, M. F., Massart, P.-E., van Eyll, C., Etienne, J., Ahn, S. A., Ghadanfar, M. M., Friedrich, T., & Pouleur, H. G. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01514-4 · Cited by 14
Self-citation
Treatment of Atrial Fibrillation and Atrial Flutter
Aronow, W. S. (2008) · Cardiology in Review · doi:10.1097/crd.0b013e3181723694 · Cited by 14
Marked QT Prolongation and Torsades de Pointes Secondary to Acute Ischemia in an Elderly Man Taking Dofetilide for Atrial Fibrillation: A Cautionary Tale
Nagra, B. S., Ledley, G. S., & Kantharia, B. K. (2005) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424840501000307 · Cited by 14
Appropriate outcome measures in trials evaluating treatment of atrial fibrillation
Connolly, S. J. (2000) · American Heart Journal · doi:10.1016/s0002-8703(00)90002-4 · Cited by 14
Intravenous antiarrhythmic agents
Pintér, A., & Dorian, P. (2001) · Current Opinion in Cardiology · doi:10.1097/00001573-200101000-00003 · Cited by 13
Electrophysiologic Effects of the New Class III Antiarrhythmic Drug Dofetilide in an Experimental Canine Model of Pacing-induced Atrial Fibrillation
Feld, G. K., & Cha, Y. (1997) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424849700200306 · Cited by 13
Pharmacological cardioversion of atrial fibrillation--a double-blind, randomized, placebo-controlled, multicentre, dose-escalation study of AZD1305 given intravenously
Rónaszéki, A., Alings, M., Egstrup, K., Gaciong, Z. A., Hranai, M., Király, C., Sereg, M., Figatowski, W., Bondarov, P., Johansson, S. A., et al. (2011) · EP Europace · doi:10.1093/europace/eur120 · Cited by 12
Cost Effectiveness of Therapies for Atrial Fibrillation
Teng, M. P., Catherwood, E., & Melby, D. P. (2000) · PharmacoEconomics · doi:10.2165/00019053-200018040-00002 · Cited by 12
What niche will newer class III antiarrhythmic drugs occupy?
Singh, B. N., & Sarma, J. S. M. (2001) · Current Cardiology Reports · doi:10.1007/s11886-001-0086-x · Cited by 12
Antiarrhythmic drug therapy of atrial fibrillation
Vernooy, R. A., & Mounsey, J. P. (2004) · Cardiology Clinics · doi:10.1016/s0733-8651(03)00116-4 · Cited by 11
Cardioversion of Atrial Fibrillation
Gowda, S. A., Shah, A. N., & Steinberg, J. S. (2005) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2005.06.006 · Cited by 11
Observations on the Safety and Effectiveness of Dofetilide in Patients With Paroxysmal Atrial Fibrillation and Normal Left Ventricular Function
Mykytsey, A., Bauman, J. L., Razminia, M., Zheutlin, T. A., Wang, T., Saleem, M., Leal, S., & Kehoe, R. (2007) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248407299272 · Cited by 11
AMERICAN COLLEGE OF CARDIOLOGY, AMERICAN HEART ASSOCIATION AND EUROPEAN SOCIETY OF CARDIOLOGY GUIDELINES (2006) FOR THE MANAGEMENT OF PATIENTS WITH ATRIAL FIBRILLATION (ENDING)
Fuster, V., Rydén, L., Cannom, D. S., Crijns, H. J. G. M., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Heuzey, J. Y. L., Kay, G. N., Lowe, J. E., et al. (2007) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2007-3-3-84-111 · Cited by 11
A New Class III Antiarrhythmic Drug Niferidil Prolongs Action Potentials in Guinea Pig Atrial Myocardium via Inhibition of Rapid Delayed Rectifier
Валерьевич, А. Д., Kuzmin, V. S., & Rosenshtraukh, L. V. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6762-x · Cited by 10
Enhancing Electrical Cardioversion and Preventing Immediate Reinitiation of Hemodynamically Deleterious Atrial Fibrillation with Class III Drug Pretreatment
Hayashi, M., Tanaka, K., Kato, T., Morita, N., Sato, N., Yasutake, M., Kobayashi, Y., & Takano, T. (2005) · Journal of Cardiovascular Electrophysiology · doi:10.1046/j.1540-8167.2005.40748.x · Cited by 10
Advances in the acute pharmacologic management of cardiac arrhythmias
Sarkozy, A., & Dorian, P. (2003) · Current Cardiology Reports · doi:10.1007/s11886-003-0096-y · Cited by 10
Comparison of the effects of DC031050, a class III antiarrhythmic agent, on hERG channel and three neuronal potassium channels
Li, P., Sun, H., Zhou, P., Ma, C.-Y., Hu, G., Jiang, H.-L., Li, M., Liu, H., & Gao, Z.-B. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2012.41 · Cited by 9
Effects of the Ikr-Blocker Almokalant and Predictors of Conversion of Chronic Atrial Tachyarrhythmias to Sinus Rhythm. A Prospective Study
Houltz, B., Darpö, B., Swedberg, K. B., Blomström, P., Brachmann, J., Crijns, H. J. G. M., Jensen, S. M., Svernhage, E., Vallin, H., & Edvardsson, N. G. (1999) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1007759500274 · Cited by 9
ECG of the Month
Armentano, R. A., Schmidt, M. K., & Maisenbacher, H. W. (2010) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.236.1.51 · Cited by 9
Effects of intravenous dofetilide in patients with frequent premature ventricular contractions: A clinical trial
Pool, P. E., Singh, S. N., & Friedrich, T. (2000) · Clinical Cardiology · doi:10.1002/clc.4960230607 · Cited by 9
Self-citation
Atrial fibrillation: Choosing an antiarrhythmic drug
Rudo, T. J., & Kowey, P. R. (2006) · Current Cardiology Reports · doi:10.1007/s11886-006-0077-z · Cited by 9
Antiarrhythmic drug therapy: what is certain and what is to come
Capucci, A. (2003) · European Heart Journal Supplements · doi:10.1016/s1520-765x(03)90018-6 · Cited by 9
Antiarrhythmic effect of nifekalant on atrial tachyarrhythmia in four patients with severe heart failure.
Shiga, T., Matsuda, N., Fuda, Y., Haruta, S., Hagiwara, N., & Kasanuki, H. (2002) · PubMed · Cited by 9
Review : Restoring Sinus Rhythm in Patients with Atrial Flutter and Fibrillation: Pharmacologic or Electrical Cardioversion?
Gallik, D. M., Altamirano, J., & Singh, B. N. (1997) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424849700200207 · Cited by 9
Effects of intravenous dofetilide on induction of atrioventricular re-entrant tachycardia
Cobbe, S. M., Campbell, R. W. F., Camm, A. J., Nathan, A. W., Rowland, E., Bloch-Thomsen, P.-E., Møller, M., & Jordaens, L. J. L. M. (2001) · Heart · doi:10.1136/heart.86.5.522 · Cited by 8
Cuándo y cómo cardiovertir la fibrilación auricular al inicio del año 2000
Morán, J. R. S. E. G. (2000) · Revista Española de Cardiología · doi:10.1016/s0300-8932(00)75126-8 · Cited by 8
External electrical and pharmacological cardioversion for atrial fibrillation, atrial flutter or atrial tachycardias: a network meta-analysis
Kukendrarajah, K., Ahmad, M., Carrington, M., Ioannou, A., Taylor, J., Razvi, Y., Παπαγεωργίου, Ν., Mead, G. E., Nevis, I., D’Ascenzo, F., et al. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013255.pub2 · Cited by 8
Executive Summary: European Heart Rhythm Association Consensus Document on the Management of Supraventricular Arrhythmias
Katritsis, D. G., Boriani, G., Cosío, F. G., Jaı̈s, P., Hindricks, G., Josephson, M. E., Keegan, R., Knight, B. P., Kück, K., Lane, D. A., et al. (2016) · Arrhythmia & Electrophysiology Review · doi:10.15420/aer.2016:5.3.gl1 · Cited by 7
Management of Dofetilide Overdose in a Patient with Known Cocaine Abuse
Campbell, K. B., Mando‐Vandrick, J., Gray, A., & Robinson, E. (2007) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.3.459 · Cited by 7
Intravenous therapy for atrial fibrillation: More choices, more questions, more trials
Ellenbogen, K. A., Wood, M. A., & Stambler, B. S. (1999) · American Heart Journal · doi:10.1016/s0002-8703(99)70349-2 · Cited by 7
Cardiac potassium currents and channels
Monsuez, J.-J. (1997) · International Journal of Cardiology · doi:10.1016/s0167-5273(97)00169-1 · Cited by 7
Reviews: Pure Class III Antiarrhythmic Drugs: Focus on Dofetilide
Doshi, S. K., & Singh, B. N. (2000) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1054/jcpt.2000.19244 · Cited by 7
Atrial Fibrillation in Patients with Heart Failure: Pharmacologic Options
Matalka, M. S., & DEEDWANIA, P. C. (2001) · Congestive Heart Failure · doi:10.1111/j.1527-5299.2001.990864.x · Cited by 7
Anti-Arrhythmic Agents in the Treatment of Atrial Fibrillation.
Of, H., Suwaidi, J. M. S. A., & Salam, A. M. (2013) · Europe PMC (PubMed Central) · doi:10.4022/jafib.864 · Cited by 6
Atrial Fibrillation
Goralnick, E., & Bontempo, L. J. (2015) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2015.04.008 · Cited by 6
Pharmacotherapy of atrial fibrillation
Němec, J., & Shen, W.-K. (1999) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.1.1.81 · Cited by 6
Antiarrhythmic drugs: new agents and evolving concepts
Němec, J., & Shen, W.-K. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.3.435 · Cited by 6
Searching for the Ideal Class III Antiarrhythmic Agent: How Pure Should They Be?
Singh, B. N. (1997) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424849700200401 · Cited by 6
Inhibition of KCa2 and Kv11.1 Channels in Pigs With Left Ventricular Dysfunction
Citerni, C., Kirchhoff, J. E., Olsen, L. H., Sattler, S. M., Grunnet, M., Edvardsson, N. G., Bentzen, B. H., & Diness, J. G. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00556 · Cited by 5
Cardioversion of recent‐onset atrial fibrillation using intravenous antiarrhythmics: A European perspective
Lévy, S. (2021) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.15264 · Cited by 6
Antiarrhythmic Drug Therapy in the Treatment of Acute and Chronic Atrial Flutter
Amadori, M., Rapacciuolo, A., & Diemberger, I. (2022) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccep.2022.05.006 · Cited by 5
Rhythm Association and the Heart Rhythm Society Developed in Collaboration With the European Heart Atrial Fibrillation): Committee to Revise the 2001 Guidelines for the Management of Patients With the European Society of Cardiology Committee for Practice Guidelines (Writing Cardiology/American Heart Association Task Force on Practice Guidelines and Fibrillation—Executive Summary: A Report of the American College of ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial
Morais, J., Osterspey, A., Tamargo, J. L., Zamorano, L., Despres, C., Dickstein, K., Lekakis, J. P., McGregor, K., Metra, M., Budaj, A., et al. (2006) · Cited by 5
Dofetilide: what role in the treatment of ventricular tachyarrhythmias?
Saoudi, N. C. (2001) · European Heart Journal · doi:10.1053/euhj.2001.2831 · Cited by 5
Supraventricular Tachyarrhythmias in the Elderly
Aronow, W. S., Banach, M., & Ahmed, A. M. (2013) · doi:10.1201/b15156-26 · Cited by 3
Pharmacological conversion of recent-onset atrial fibrillation: a randomized study of propafenone and amiodarone
Kamil, G., Kamal, A., & Ahmed, N. (2019) · Menoufia Medical Journal · doi:10.4103/mmj.mmj_748_17 · Cited by 4
Class III Antiarrhythmic Drugs
Tamargo, J. L., Caballero, R., & Delpón, E. (2020) · Springer eBooks · doi:10.1007/978-3-030-34893-9_3 · Cited by 4
ECG of the Month
Vezzosi, T., Domenech, O., Cipollini, C., Cantile, C., Côté, É., & Tognetti, R. (2019) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.255.11.1234 · Cited by 4
Cardiac Drugs: Antianginal, Vasodilators, and Antiarrhythmics
Joshi, G. S., Burnett, J. C., & Abraham, D. J. (2003) · Wiley eBooks · doi:10.1002/0471266949.bmc041 · Cited by 4
Atrial fibrillation in the elderly
Chen, J., & Rich, M. W. (2003) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-003-0042-8 · Cited by 3
Evaluation of initial dofetilide dosing recommendation based on actual body weight in overweight and obese patients
Cao, D. X., Kohatsu, A., Eng, L., Mei, K., Dinh, J., Mok, I., Moreau, N., Le, A., & Shin, J. (2015) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12321 · Cited by 3
Antiarrhythmic Drugs
Dobrev, D., & Singh, B. N. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0285-9.00082-x · Cited by 3
¿Hacia dónde se dirige la investigación sobre fibrilación auricular?
García-Cosío, F. (2000) · Revista Española de Cardiología · doi:10.1016/s0300-8932(00)75235-3 · Cited by 3
Clinical Potential of Emerging Antiarrhythmic Agents
Capucci, A., Aschieri, D., VILLANI, G. Q., & Piepoli, M. F. (1999) · Drugs in R&D · doi:10.2165/00126839-199901040-00001 · Cited by 3
Oral d,l-sotalol in atrial fibrillation and/or flutter
Cosío, F. G. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00803-6 · Cited by 3
Effect of Na and K channel blockers on the spatial and temporal dispersions of atrial refractoriness during atrial fibrillation.
Shinagawa, K., Mitamura, H., Sato, T., Kanki, H., Takatsuki, S., & Ogawa, S. (1998) · Japanese Journal of Electrocardiology · doi:10.5105/jse.18.433 · Cited by 3
Medikamentöse Kardioversion von Vorhofflimmern
Ehrlich, J. R., & Hohnloser, S. H. (2005) · Zeitschrift für Kardiologie · doi:10.1007/s00392-005-0166-9 · Cited by 3
Characterization of hERG K+ channel inhibition by the new class III antiarrhythmic drug cavutilide
Валерьевич, А. Д., Pustovit, K. B., Mironov, N. Y., Filatova, T. S., & Nesterova, T. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02940-5 · Cited by 2
The Dependence of the Electrophysiological Effects of Class III Antiarrhythmic Drug Refralon on the Frequency of Myocardium Activation
Валерьевич, А. Д., Pustovit, K. B., Mironov, N. Y., Filatova, T. S., & Kuzmin, V. S. (2023) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-023-05756-8 · Cited by 2
Pharmacologic Conversion of Atrial Fibrillation and Atrial Flutter
Marinelli, A., & Capucci, A. (2010) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccep.2010.06.002 · Cited by 2
Management of the patient in atrial fibrillation
Wyse, D. G. (1997) · Evidence-based Cardiovascular Medicine · doi:10.1016/s1361-2611(97)80049-8 · Cited by 2
Dofetilide Effects on the Inhibition by Trains of Subthreshold Conditioning Stimuli
Chorro, F. J., FERRERO, A., Sáiz, J., SANCHIS, J., Porres, J. C., Mainar, L., Cánoves, J., Blasco, E., López‐Merino, V., & Such, L. (2004) · Pacing and Clinical Electrophysiology · doi:10.1111/j.1540-8159.2004.00436.x · Cited by 2
Pharmakologische Therapie von Vorhofflimmern und Vorhofflattern
Grönefeld, G., Li, Y., & Hohnloser, S. H. (2002) · Herz · doi:10.1007/s00059-002-2390-7 · Cited by 2
Algorithms useful in the treatment of atrial fibrillation
Chaudhry, G. M., & Haffajee, C. I. (2002) · Current Opinion in Cardiology · doi:10.1097/00001573-200201000-00008 · Cited by 2
Special Considerations for the Elderly Patient with Atrial Fibrillation
Aronow, W. S. (2001) · Cardiac Electrophysiology Review · doi:10.1023/a:1011409622823 · Cited by 1
Atrial Fibrillation Management in Elderly
Aronow, W. S. (2012) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-012-0263-z · Cited by 1
Cardiac Arrhythmias
Aronow, W. S. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6231-8.10045-5 · Cited by 1
Acetylcholine-Activated Potassium Channel as a Novel Target for AF Treatment
Hashimoto, N. (2012) · InTech eBooks · doi:10.5772/27521 · Cited by 1
Cardioversion of Recent Onset Atrial Fibrillation: Which Drug to Prefer in the Individual Patient?
Vardas, P. E., & Kanoupakis, E. M. (2004) · Springer eBooks · doi:10.1007/978-88-470-2137-2_8 · Cited by 1
Atrial Fibrillation: Rhythm and Rate Control Therapies
Savelieva, I., Waldo, A. L., & Camm, A. J. (2009) · Wiley eBooks · doi:10.1002/9781444309768.ch35 · Cited by 1
Excitable Gap, Antiarrhythmic Actions, Electrical Remodeling: The Role Of MAP Recording in Atrial Fibrillation And Other Atrial Tachyarrhythmias
Franz, M. R. (1997) · Springer eBooks · doi:10.1007/978-3-642-60851-3_9 · Cited by 1
Narrow complex tachycardia: recognition and management in the emergency room.
Ib, R. (2004) · PubMed · Cited by 1
Cardiovascular Agents
Joshi, G. S., & Burnett, J. C. (2003) · Wiley eBooks · doi:10.1002/0471238961.0301180403051822.a01.pub2 · Cited by 1
Conversion of Atrial Fibrillation: Pills, Shots, or Shocks?
Podrid, P. J. (1998) · Cardiac Electrophysiology Review · doi:10.1023/a:1009958911119 · Cited by 1
Overview of Atrial Fibrillation Trials
Wyse, D. G. (2000) · Cardiac Electrophysiology Review · doi:10.1023/a:1009911030742 · Cited by 1
Approach to the Patient with Atrial Fibrillation
Costantini, O., & Stambler, B. S. (2002) · Contemporary cardiology · doi:10.1007/978-1-59259-090-2_5 · Cited by 1
Pharmacological Control of Rate and Maintenance of Sinus Rhythm
Ezekowitz, M. D., & Lampert, R. (1999) · Journal of Thrombosis and Thrombolysis · doi:10.1023/a:1008823202712 · Cited by 1
Acute Termination of Atrial Flutter: Are New Class Antiarrhythmic Drugs the Best Choice?
Baldi, N., Russo, V., Morrone, V., Gregorio, L. D., Liconso, L., & Polimeni, G. (2002) · Springer eBooks · doi:10.1007/978-88-470-2103-7_43
Role of Implantable Atrial Defibrillators in the Treatment of Atrial Fibrillation
Jordaens, L. J. L. M. (1998) · Developments in cardiovascular medicine · doi:10.1007/978-94-011-5254-9_36
ANTIARRHYTHMIC THERAPY FOR ATRIAL TACHYARRHYTHMIAS
Lambić, I. (1999)
Acute Conversion of Recent-Onset Atrial Fibrillation and Flutter: Class IC or Class III Drugs?
Rf, G., Chen, C. H., & Bracchetti, D. (2000) · Springer eBooks · doi:10.1007/978-88-470-2139-6_8
Can atrial flutter be converted to sinus rhythm by antiarrhythmic drugs or should atrial pacing be performed
Hief, C., Klösch, C., Podczeck, A., & Steinbach, K. (1999) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Cost-Effective Care in the Management of Conduction Disease and Arrhythmias
Malenka, D. J., & Catherwood, E. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-398-9_18
Review of the current management of atrial fibrillation
Gould, P. A., Power, J., Broughton, A., & Kaye, D. M. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.11.1889
ESC COMMITTEE FOR PRACTICE GUIDELINES & POLICY CONFERENCES MEMBERS
Fuster, V., Wann, L. S., McNamara, R. L., Prystowsky, E. N., Gibbons, R. J., Antman, E. M., Alpert, J. S., & Gregoratos, G. (2001)
Pharmacologic Management of Atrial Fibrillation and Flutter
Saluja, D. S., Hickey, K. T., & Reiffel, J. A. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-161-5_8
Medikamentöse und alternative Konzepte zur Behandlung von Vorhofflimmern: Neuere Klasse-III-Antiarrhythmika, Hybridtherapien (Kardioversion-Defibrillation, Ablation, Pacing)
Pürerfellner, H. (2004) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Acute Termination of Atrial Flutter: Class III Drugs or Transesophageal Pacing?
Bonso, A., Themistoclakis, S., Rossillo, A., & Raviele, A. (2004) · Springer eBooks · doi:10.1007/978-88-470-2137-2_34
Update on Antiarrhythmic Therapy: Dofetilide
Wang, Q., TSE, H.-F., & Lau, C. (2022) · Journal of the Hong Kong College of Cardiology · doi:10.55503/2790-6744.1466
RECOGNIZING AND RESPONDING TO AN ATTACK WITH A BIOLOGICAL WEAPON
Schmitt, B. P., Bhattacharya, M., & Gerding, D. N. (2001) · Southern Medical Journal · doi:10.1097/00007611-200111000-00002
Pharmacologic Management of Atrial Fibrillation
Finkle, J. K., Plunkitt, K., & Kowey, P. R. (2002) · Contemporary cardiology · doi:10.1007/978-1-59259-090-2_6
Pharmacological defibrillation and its mechanism in atrial fibrillation. The efficacy of a pure class III agent dofetilide as compared with class I antiarrhythmic agents.
Kobayashi, Y., & Atarashi, H. (1998) · Japanese Journal of Electrocardiology · doi:10.5105/jse.18.333
Pharmacologic of Atrial Fibrillation and Atrial Flutter
Marinelli, A., & Capucci, A. (2010)
Dofetilideof its Use in Atrial Fibrillation and Atrial Flutter
Carmeliet, E. E., Frost, L., Funck‐Brentano, C., Kobayashi, Y., & Møller, M. (1999)
Treatment of Acute Atrial Fibrillation: Ventricular Rate Control and Restoration of Sinus Rhythm
Fung, H., & Kam, C. W. (2000) · Hong Kong Journal of Emergency Medicine · doi:10.1177/102490790000700205 · Cited by 1
Immediate Management of Atrial Fibrillation: State of the Art
Flaker, G. C., & Nasr, S. (2001) · Cardiac Electrophysiology Review · doi:10.1023/a:1011480700533
第32回理論心電図研究会テーマ : 心房細動・粗動の基礎と臨床―基礎の立場から― 心房細動の薬物治療
博次, 新. (1998) · 心臓 · doi:10.11281/shinzo1969.30.4_263
Cardiac Arrhythmias
Klinkman, M. S. (2005) · Springer eBooks · doi:10.1007/0-387-27276-3_3
Supraventricular Tachyarrhythmias in the Elderly
Aronow, W. S., & Sorbera, C. A. (2008) · Fundamental and clinical cardiology · doi:10.3109/9781420061710.022
Common Atrial and Ventricular Arrhythmias
Foreman, B. W. (2018) · Contemporary cardiology · doi:10.1007/978-3-319-97622-8_23
Dofetilide
Cada, D. J., Baker, D. E., & Levien, T. L. (2000) · Hospital Pharmacy · doi:10.1177/001857870003500506

Authors: Falk, R. H., Pollak, A., Singh, S. N., & Friedrich, T.
Affiliations: Boston Medical Center (US)
Corresponding author: Falk, Rodney H.
ORCID: Falk, Rodney H.
Pollak, Arthur
Singh, Steven N.
Venue: Journal of the American College of Cardiology
Publisher: Elsevier BV
Published: 1997-02
Volume: 29
Issue: 2
Pages: 385-390
ISSN: 0735-1097 (ISSN-L)
DOI: 10.1016/s0735-1097(96)00506-2
OpenAlex: W2003632755
Cited by: 215
References: 30
Citations by year: 2025: 3 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 4 · 2019: 4 · 2018: 2 · 2017: 2 · 2016: 7 · 2015: 4 · 2013: 4 · 2012: 5
FWCI: 15.58
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 1208 d)
Locations: Journal of the American College of Cardiology (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Arrhythmias and Treatments
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
Keywords: dofetilide, intravenous administration, class III antiarrhythmic agents, sustained atrial fibrillation, atrial flutter, conversion to sinus rhythm, action potential prolongation
MeSH terms: Anti-Arrhythmia Agents, Atrial Fibrillation, Atrial Flutter, Double-Blind Method, Hemodynamics, Humans, Phenethylamines, Sulfonamides, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Intravenous Dofetilide, a Class III Antiarrhythmic Agent, for the Termination of Sustained Atrial Fibrillation or Flutter

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks